Connect with us

Alto Neuroscience

Alto Neuroscience says its funded through 2028

Published

on



Alto Neuroscience, Inc. (NYSE: ANRO) reported financial results for the full year ending December 31, 2024, highlighting recent progress across its pipeline of clinical-stage product candidates. The company also provided upcoming milestones it expects to reach and assured investors about its financial stability.

Alto Neuroscience had a successful IPO in 2024 that gave the company a cash cushion that it said would fund the company through 2028. At the end of 2024, Alto had cash, cash equivalents, and restricted cash of approximately $169 million, compared to approximately $83 million at the end of 2023. The company reported a net loss of $61.4 million for 2024 versus a net loss of $36.3 million for 2023. The company ahs no revenues to report at this time.

“In 2024 we continued to advance our mission to change the way medicines are developed for neuropsychiatric conditions,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “Using our proprietary platform we have evaluated brain-based biomarkers in over 2,000 participants and have completed six clinical studies across our pipeline programs since our founding. Further, we believe the outcome of the recent interim analysis of the ongoing ALTO-300 trial is suggestive of antidepressant activity, and we believe the sample re-estimation improves the overall probability of success in that trial.”

Expenses

The company reported that its research and development expenses for the full year were $47.0 million versus 2023’s $30.3 million. The company attributed the change to increased personnel costs; including $1.5 million of non-cash, stock-based compensation; as well as costs associated with the Phase 2b clinical study for ALTO-300, and the Phase 2 POC studies for ALTO-203 and ALTO-101.

General and administrative expenses were $21.6 million, also higher than 2023’s $7.5 million. The increase was due to costs associated with higher headcount to support expanded clinical development efforts, growing operational requirements, and costs associated with operating as a public company. $3.3 million of the increase is reflective of non-cash, stock-based compensation.

Pipeline

ALTO-100 is in development for the treatment of bipolar depression (BPD). The company had reported in October that its Phase2b study didn’t deliver the desired results. Alto said that upon further discovery, it learned that the patients had a lower rate of medication compliance. the company said it reviewed the results of the patients who had complied and found the results worth continuing the study. The company said enrollment in the randomized, double-blind, placebo-controlled Phase 2b trial remains ongoing with topline data expected in the second half of 2026.

ALTO-300 is being developed as an adjunctive treatment in the United States for patients with MDD (major depressive disorder). The company said topline data from the double-blind, placebo-controlled, randomized Phase 2b trial is expected in mid-2026.

ALTO-203 is being developed for the treatment of MDD associated with increased levels of anhedonia. In February, Alto reported it completed enrollment in the Phase 2 proof-of-concept (POC) trial in MDD patients with higher levels of anhedonia. The company said it expects to report topline data in the second quarter of 2025.

ALTO-101  is being developed for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The company reported that enrollment is ongoing in the Phase 2 POC (proof of concept) trial in CIAS, with topline data expected in the second half of 2025.

Dr. Etkin added, “Successfully completing our IPO in 2024 has provided us with a strong balance sheet to support several key clinical milestones in the coming years. As a scientific founder with a sincere passion to move the field forward, I am very proud of all our team has accomplished and I look forward to building on this momentum.”



Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Mississippi Cannabis News6 hours ago

Mississippi AG takes aim at hemp products, including Delta THC | TN State News

Mississippi Cannabis News7 hours ago

Mississippi AG takes aim at hemp products, including Delta THC | State

featured13 hours ago

Weed Jobs Are the Happiest Jobs in America, Says New Report

video15 hours ago

New York cannabis board approves 52 new licenses, pushes total to 1,851

video16 hours ago

The Maricopa County Sheriff; cannabis in Arizona | Newsmaker

featured17 hours ago

Missouri Marijuana Regulators Have Completed About Half Of 16,000 Industry Workers’ Background Checks

featured18 hours ago

Pennsylvania Lawmakers And Activists Agree On Legalizing Marijuana, But Differ On What Business Model Is Best

featured2 days ago

Rhode Island Officials Pause New Hemp Retailer Licenses As They Study Sales Of THC Drinks In Liquor Stores And Bars

featured2 days ago

Broader Launch Of Minnesota’s Marijuana Retail Market Is Almost Here, State Officials Say

featured2 days ago

Bipartisan Coalition Of 32 Attorneys General Pushes Congress To Urgently Pass Marijuana Banking Bill

featured2 days ago

Marijuana And CBD Provide ‘Significant Symptom Relief’ For Inflammatory Bowel Disease Patients, Federally Funded Study Finds

featured2 days ago

Doctor Who Allegedly Said ‘I Wonder How Much This Moron Will Pay’ Pleads Guilty

video2 days ago

Killing reported at Oklahoma marijuana grow operation

featured2 days ago

Texas Voters Want Synthetic THC Outlawed, Poll Shared By Proponents Of Reining In Hemp Industry Finds

video2 days ago

Judge rejects No Savage’s rap culture argument – NBC4 Washington

featured2 days ago

California Moves to Ban Hemp Wellness Products — And the Weed Nuns Are Fighting Back

featured2 days ago

Cannabis & Psychedelics Reported Most Effective Non-Prescription Drugs by Eating Disorder Patients

featured2 days ago

Kentucky Governor Urges Trump To Oppose Bill Blocking Marijuana Rescheduling That’s Advancing In Congress

video2 days ago

New York cannabis board approves 52 new licenses, pushes total to 1,851

featured2 days ago

South Park Loves Marijuana – The Fresh Toast

featured2 days ago

Lo Más Reciente de High Times en Español

featured3 days ago

DEA Judge Overseeing Cannabis Rescheduling Process Retires

featured3 days ago

GOP Senator Threatens To Block Spending Bill If Hemp THC Product Ban Stays In, Sources Say

featured3 days ago

The Best Delicious Summer Cocktails

Trending